Current Portfolio

Pelorus Life Sciences Fund

The Pelorus Life Sciences Fund (PLSF) is a concentrated portfolio of small and mid-cap biotechnology companies with near-term catalysts that can materially re-rate the valuation. We focus on disease areas where we have expertise and avoid those where we don't. Our process integrates robust scientific analysis, competitive intelligence, smart-money ownership signals, management quality, and stakeholder research into a proprietary quantitative framework designed to deliver repeatable, disciplined investment decisions.

Core Investment Strategy

Long-biased with tactical hedging: Predominantly long equity with selective use of options to manage downside risk or enhance returns around binary catalysts.
Concentrated and diversified: Typically 30-45 positions, with most holdings under 5% of the portfolio, balancing conviction with prudent risk management across a volatile sector.
Catalyst-driven: Investments are selected based on identifiable events — clinical data readouts, regulatory decisions, strategic transactions — generally expected within 0-18 months.

Research-intensive: Decisions are informed by rigorous analysis of clinical data, competitive positioning, intellectual property, management quality, balance sheet strength, and valuation, supported by a proprietary quantitative scoring framework.
Thesis-driven: Positions are generally held for multi-quarter to multi-year periods, allowing the Fund to capture full value realization rather than trading short-term volatility.
Benchmark-accountable: Measured against XBI, the Fund seeks to consistently outperform the innovative biotech segment and combat sector cyclicality with catalyst-driven investments.